Live Breaking News & Updates on Glenn Goddard

Stay updated with breaking news from Glenn goddard. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Q4 2023 Earnings Call Transcript February 22, 2024 Intellia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-1.46, expectations were $-1.47. Intellia Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome […] ....

Laura Sepp Lorenzino , Maury Raycroft , Glenn Goddard , New England Journal , Intellia In Vivo , Chief Scientific Officer , Recode Therapeutics , Allo Solution , Chief Financial Officer , Wind Power , Solar Stocks To Buy , Growing Economies , John Leonard , Intellia Therapeutics , David Lebwohl , Chief Executive Officer , Perator Instructions , Chief Scientific Officer , Fourth Quarter ,

Aigen Investment Management LP Takes Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Aigen Investment Management LP purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 17,569 shares of the company’s stock, valued at approximately $556,000. Other institutional investors have also made changes to […] ....

Glenn Goddard , Johnm Leonard , Dekabank Deutsche Girozentrale , Securities Exchange Commission , Intellia Therapeutics Inc , Envestnet Asset Management Inc , Rafferty Asset Management , Royal Bank , Fund Management Co , Morgan Stanley , Wolfe Research , Aigen Investment Management , Intellia Therapeutics , Free Report , Asset Management , Bank Deutsche Girozentrale , Fund Management , Rhumbline Advisers , Exchange Commission , Intellia Therapeutics Daily , Nasdaq Ntla , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

Wedbush Reiterates "Neutral" Rating for Intellia Therapeutics (NASDAQ:NTLA)

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “neutral” rating reaffirmed by equities research analysts at Wedbush in a research note issued on Thursday, RTT News reports. They presently have a $29.00 price objective on the stock. Wedbush’s price target would indicate a potential upside of 1.86% from the company’s current price. Other […] ....

David Lebwohl , Glenn Goddard , Norges Bank , Intellia Therapeutics Inc , Wolfe Research , Investment Management , Royal Bank , Morgan Stanley , Intellia Therapeutics , Get Free Report , Partners Asset Management , State Street Corp , Street Corp , Intellia Therapeutics Daily , Nasdaq Ntla , Reiterated Rating ,